Monoamine oxidase deficiency
May. 14, 2024
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.
The various chemical intermediates are shown in black text with their structural formulae. The responsible enzymes that catalyze each step in the pathway are shown in blue. Enzyme inducers are shown in green and enzyme inhibitors are shown in red. Also shown in red are the diseases and associated symptoms resulting from partial function of two of these enzymes: acute intermittent porphyria resulting from partial function of the PBG-deaminase enzyme, and porphyria cutanea tarda resulting from partial function of the UPG III-decarboxylase enzyme. (Original figure by Clindberg, modified by Ross Boswell. Courtesy of Wikimedia Commons. Creative Commons Attribution-Share Alike 3.0 Unported license.)